Conclusively, our results suggest that the diagnostic value of CRP should be reconsidered in the era of biologics and that serum VEGF could be an alternative to ESR and CRP, which are the two widely accepted biomarkers of RA activity. The gene discussed is VEGFA; the disease is rheumatoid arthritis.